Advertisement

Archives of Toxicology

, Volume 93, Issue 7, pp 2045–2055 | Cite as

Angiotensin II-induced hypertension increases the mutant frequency in rat kidney

  • Christina Hartmann
  • Ina Schulz
  • Bernd Epe
  • Nicole SchuppEmail author
Genotoxicity and Carcinogenicity

Abstract

Epidemiological studies revealed an increased risk for kidney cancer in hypertensive patients. In many of these patients, the blood pressure regulating renin–angiotensin–aldosterone system (RAAS) is activated. A stimulated RAAS leads to oxidative stress and increases markers of DNA damage, both in vitro and in animal models of hypertension. However, the mutagenic potential of RAAS activation has not been investigated yet. To quantify hypertension-induced mutations, BigBlue®+/− rats, which carry a transgenic lacI gene for mutation analysis, were treated for 20 weeks with a mean dose of 400 µg angiotensin II/kg × day. Angiotensin II-treated animals showed significantly increased blood pressure and impaired kidney function. Urinary excretion of oxidized nucleobases was raised. Additionally, in the renal cortex, oxidative stress, oxidatively generated DNA lesions and DNA strandbreaks were significantly increased. Further, a significant elevation of the mutant frequency in kidney DNA was detected. Sequencing revealed the presence of GC → T:A transversions in the mutated lacI genes of the angiotensin II-treated animals as a result of unrepaired oxidatively modified DNA bases, while no such transversions were found in the mutated lacI genes from control animals. The results demonstrate that the oxidative stress and DNA damage previously observed in kidney cells in vitro and in vivo after angiotensin II treatment indeed is associated with the accumulation of mutations in rat kidneys, providing further evidence for a cancer-initiating potential of elevated angiotensin II concentrations.

Keywords

Angiotensin II Hypertension Mutation frequency BigBlue® 8-oxoG Oxidative stress 

Notes

Acknowledgements

The outstanding technical assistance of Kerstin De Mezzo is acknowledged. We thank Iris Schrey and Mandy Knitter for their excellent help during our operations, Stephanie Pohlmann for her help with the perfusion and Annegret Rosner and Wolfgang Manz for the considerate care of our rats.

Author contributions

NS, and BE designed the study, CH and IS carried out experiments and analyzed the data, CH, NS and BE: drafted and revised the manuscript, all authors approved the final version of the manuscript.

Funding

This work was supported by the Deutsche Krebshilfe (#110667 to N. S. and #110668 to B. E.).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All animal experiments were performed in accordance with the European Community guidelines for the use of experimental animals and with the German law for the protection of animals (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, permit number 84-02.04.2014.A386). The investigation conformed to the “Guide for the Care and Use of Laboratory Animals” published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996).

Research involving human participant

This article does not contain any studies with human participants performed by any of the authors.

References

  1. Asakawa S, Shibata S, Morimoto C et al (2017) Podocyte injury and albuminuria in experimental hyperuricemic model rats. Oxidat Med Cell Longev 2017:3759153.  https://doi.org/10.1155/2017/3759153 CrossRefGoogle Scholar
  2. Bangalore S, Kumar S, Kjeldsen SE et al (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 12(1):65–82CrossRefPubMedGoogle Scholar
  3. Bol SA, Horlbeck J, Markovic J, de Boer JG, Turesky RJ, Constable A (2000) Mutational analysis of the liver, colon and kidney of Big Blue rats treated with 2-amino-3-methylimidazo[4,5-f]quinoline. Carcinogenesis 21(1):1–6CrossRefPubMedGoogle Scholar
  4. Brand S, Amann K, Schupp N (2013) Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts. J Hypertens 31(2):333–344CrossRefPubMedGoogle Scholar
  5. Brand S, Amann K, Mandel P, Zimnol A, Schupp N (2014) Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors. PLoS One 9(12):e115715.  https://doi.org/10.1371/journal.pone.0115715 CrossRefPubMedPubMedCentralGoogle Scholar
  6. Chen L, Mei N, Yao L, Chen T (2006) Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol Lett 165(3):250–256.  https://doi.org/10.1016/j.toxlet.2006.04.008 CrossRefPubMedGoogle Scholar
  7. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—T and A—C substitutions. J Biol Chem 267(1):166–172PubMedGoogle Scholar
  8. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343(18):1305–1311CrossRefPubMedGoogle Scholar
  9. Colt JS, Schwartz K, Graubard BI et al (2011) Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology (Cambridge, Mass) 22(6):797–804.  https://doi.org/10.1097/ede.0b013e3182300720 CrossRefGoogle Scholar
  10. de Boer JG, Mirsalis JC, Provost GS, Tindall KR, Glickman BW (1996) Spectrum of mutations in kidney, stomach, and liver from lacI transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate. Environ Mol Mutagen 28(4):418–423.  https://doi.org/10.1002/(SICI)1098-2280(1996)28:4%3c418:AID-EM17%3e3.0.CO;2-I CrossRefPubMedGoogle Scholar
  11. Dhein S, Grassl M, Gerdom M et al (2015) Organ-protective effects on the liver and kidney by minocycline in small piglets undergoing cardiopulmonary bypass. Naunyn Schmiedebergs Arch Pharmacol 388(6):663–676.  https://doi.org/10.1007/s00210-015-1115-4 CrossRefPubMedGoogle Scholar
  12. Dycaico MJ, Provost GS, Kretz PL, Ransom SL, Moores JC, Short JM (1994) The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat Res 307(2):461–478CrossRefPubMedGoogle Scholar
  13. Flaherty KT, Fuchs CS, Colditz GA et al (2005) A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 16(9):1099–1106CrossRefPubMedGoogle Scholar
  14. Gordish KL, Beierwaltes WH (2016) Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model. Integr Blood Press Control 9:23–31.  https://doi.org/10.2147/IBPC.S96092 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Grossman E, Messerli FH, Boyko V, Goldbourt U (2002) Is there an association between hypertension and cancer mortality? Am J Med 112(6):479–486CrossRefPubMedGoogle Scholar
  16. Hamet P (1997) Cancer and hypertension: a potential for crosstalk? J Hypertens 15(12 Pt 2):1573–1577CrossRefPubMedGoogle Scholar
  17. Heinmoller PW, Hill KA, Sommer SS (2000) High plating density improves Big Blue system efficiency without loss of sensitivity. Mutat Res 453(1):97–103CrossRefPubMedGoogle Scholar
  18. Jakubczak JL, Merlino G, French JE et al (1996) Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc Natl Acad Sci USA 93(17):9073–9078CrossRefPubMedGoogle Scholar
  19. Karanovic D, Grujic-Milanovic J, Miloradovic Z et al (2016) Effects of single and combined losartan and tempol treatments on oxidative stress, kidney structure and function in spontaneously hypertensive rats with early course of proteinuric nephropathy. PLoS One 11(8):e0161706.  https://doi.org/10.1371/journal.pone.0161706 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Kawarazaki H, Ando K, Nagae A, Fujita M, Matsui H, Fujita T (2010) Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. Nephrol Dial Transpl 25(9):2879–2889.  https://doi.org/10.1093/ndt/gfq197 CrossRefGoogle Scholar
  21. Kohler SW, Provost GS, Fieck A et al (1991) Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci USA 88(18):7958–7962CrossRefPubMedGoogle Scholar
  22. Lea WB, Kwak ES, Luther JM et al (2009) Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 75(9):936–944.  https://doi.org/10.1038/ki.2009.9 CrossRefPubMedPubMedCentralGoogle Scholar
  23. Lindholm LH, Anderson H, Ekbom T et al (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358(9281):539–544CrossRefPubMedGoogle Scholar
  24. Lindholm LH, Carlberg B (2011) Blood-pressure drugs and cancer: much ado about nothing? Lancet Oncol 12(1):6–8.  https://doi.org/10.1016/S1470-2045(10)70271-0 CrossRefPubMedGoogle Scholar
  25. Messerli FH, Bangalore S, Torp-Pedersen C, Staessen JA, Kostis JB (2013) Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d’Alembert. Eur Heart J 34(15):1095–1098.  https://doi.org/10.1093/eurheartj/ehs158 CrossRefPubMedGoogle Scholar
  26. Meyer P (1987) Increased intracellular calcium: from hypertension to cancer. J Hypertens Suppl 5(4):S3–S4CrossRefPubMedGoogle Scholar
  27. Nishikawa A, Furukawa F, Kasahara K et al (1997) Comparative study on organ-specificity of tumorigenicity, mutagenicity and cell proliferative activity induced by dimethylnitrosamine in Big Blue mice. Cancer Lett 117(2):143–147CrossRefPubMedGoogle Scholar
  28. Osorio H, Coronel I, Arellano A, Franco M, Escalante B, Bautista R (2012) Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract 97(2):276–282.  https://doi.org/10.1016/j.diabres.2012.02.022 CrossRefPubMedGoogle Scholar
  29. Pech V, Sikka SC, Sindhu RK, Vaziri ND, Majid DS (2006) Oxidant stress and blood pressure responses to angiotensin II administration in rats fed varying salt diets. Am J Hypertens 19(5):534–540.  https://doi.org/10.1016/j.amjhyper.2005.11.008 CrossRefPubMedGoogle Scholar
  30. Prtenjaca A, Tarnowski HE, Marr AM et al (2014) Relatively high rates of G: C – > A: T transitions at CpG sites were observed in certain epithelial tissues including pancreas and submaxillary gland of adult big blue(R) mice. Environ Mol Mutagen 55(1):51–63.  https://doi.org/10.1002/em.21816 CrossRefPubMedGoogle Scholar
  31. Queisser N, Amann K, Hey V, Habib SL, Schupp N (2013) Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo. Free Radic Biol Med 54:17–25CrossRefPubMedGoogle Scholar
  32. Queisser N, Oteiza PI, Stopper H, Oli RG, Schupp N (2011) Aldosterone induces oxidative stress, oxidative DNA damage and NF-kappaB-activation in kidney tubule cells. Mol Carcinog 50(2):123–135CrossRefPubMedGoogle Scholar
  33. Queisser N, Schupp N, Schwarz E, Hartmann C, Mackenzie GG, Oteiza PI (2017) Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox-regulated mechanisms. Mol Carcinog 56(8):1868–1883.  https://doi.org/10.1002/mc.22643 CrossRefPubMedGoogle Scholar
  34. Sasser JM, Cunningham MW Jr, Baylis C (2014) Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Renal Physiol 307(12):F1355–F1362.  https://doi.org/10.1152/ajprenal.00407.2014 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Sasser JM, Moningka NC, Cunningham MW Jr, Croker B, Baylis C (2010) Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol 298(3):R740–R746.  https://doi.org/10.1152/ajpregu.90875.2008 CrossRefPubMedGoogle Scholar
  36. Schmid U, Stopper H, Schweda F, Queisser N, Schupp N (2008) Angiotensin II induces DNA damage in the kidney. Cancer Res 68(22):9239–9246CrossRefPubMedGoogle Scholar
  37. Schupp N, Kolkhof P, Queisser N et al (2011) Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25(3):968–978CrossRefPubMedGoogle Scholar
  38. Schupp N, Schmid U, Rutkowski P et al (2007) Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol 292(5):F1427–F1434CrossRefPubMedGoogle Scholar
  39. Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE (1999) Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 149(6):521–530CrossRefPubMedGoogle Scholar
  40. Singh A, Bangalore S (2012) Which, if any, antihypertensive agents cause cancer? Curr Opin Cardiol 27(4):374–380.  https://doi.org/10.1097/HCO.0b013e328353bc4f CrossRefPubMedGoogle Scholar
  41. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11(7):627–636CrossRefPubMedPubMedCentralGoogle Scholar
  42. Suzuki T, Itoh T, Hayashi M et al (1996) Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice. Environ Mol Mutagen 28(4):348–353.  https://doi.org/10.1002/(SICI)1098-2280(1996)28:4%3c348:AID-EM8%3e3.0.CO;2-7 CrossRefPubMedGoogle Scholar
  43. Umemura T, Kanki K, Kuroiwa Y et al (2006) In vivo mutagenicity and initiation following oxidative DNA lesion in the kidneys of rats given potassium bromate. Cancer Sci 97(9):829–835.  https://doi.org/10.1111/j.1349-7006.2006.00248.x CrossRefPubMedGoogle Scholar
  44. Upadhyay A, Larson MG, Guo CY et al (2011) Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transpl 26(3):920–926.  https://doi.org/10.1093/ndt/gfq471 CrossRefGoogle Scholar
  45. Weikert S, Boeing H, Pischon T et al (2008) Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 167(4):438–446CrossRefPubMedGoogle Scholar
  46. Whitehouse W, Quimby J, Wan S, Monaghan K, Robbins R, Trepanier LA (2017) Urinary F2 -isoprostanes in cats with international renal interest society stage 1–4 chronic kidney disease. J Vet Intern Med 31(2):449–456.  https://doi.org/10.1111/jvim.14634 CrossRefPubMedPubMedCentralGoogle Scholar
  47. Whitworth JA, World Health Organization ISoHWG (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21(11):1983–1992.  https://doi.org/10.1097/01.hjh.0000084751.37215.d2 CrossRefPubMedGoogle Scholar
  48. Yamaguchi T, Wei M, Hagihara N, Omori M, Wanibuchi H, Fukushima S (2008) Lack of mutagenic and toxic effects of low dose potassium bromate on kidneys in the Big Blue rat. Mutat Res 652(1):1–11.  https://doi.org/10.1016/j.mrgentox.2007.11.004 CrossRefPubMedGoogle Scholar
  49. Yang H, Glickman BW, de Boer JG (2002) Sex-specific induction of mutations by PhIP in the kidney of male and female rats and its modulation by conjugated linoleic acid. Environ Mol Mutagen 40(2):116–121.  https://doi.org/10.1002/em.10096 CrossRefPubMedGoogle Scholar
  50. Zimnol A, Amann K, Mandel P, Hartmann C, Schupp N (2017) Angiotensin II type 1a receptor-deficient mice develop angiotensin II-induced oxidative stress and DNA damage without blood pressure increase. Am J Physiol Renal Physiol.  https://doi.org/10.1152/ajprenal.00183.2017 CrossRefPubMedGoogle Scholar
  51. Zou AP, Cowley AW Jr (1997) Nitric oxide in renal cortex and medulla. An in vivo microdialysis study. Hypertension 29(1 Pt 2):194–198CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Toxicology, Medical FacultyUniversity of DüsseldorfDüsseldorfGermany
  2. 2.Institute of Pharmacy and BiochemistryUniversity of MainzMainzGermany

Personalised recommendations